We’re excited to share that our Co-founder and CSO Umberto Battisti will be presenting at the AACR Annual Meeting 2026 in San Diego!
The poster, “Efficacy of targeted radionuclide therapy using ¹³¹I-FAPi dimers labeled via tetrazine ligation in a human glioblastoma xenograft model,” has been selected for presentation in the session Radiopharmaceutical Platforms for Theranostic Precision Oncology.
This work highlights the potential of tetrazine ligation to support the development of targeted radionuclide therapies and reflects our continued efforts to advance the TetraKit platform for precision oncology.
📍 Poster Section 16
🗓️ April 21, 2026 from 2:00 – 5:00 PM
We look forward to presenting this work during the poster session!
